Floatz logo

Doxycycline

Hermansky-Pudlak Syndrome (HPS)

National Human Genome Research Institute (NHGRI)Small moleculePhase 1/2Dormant
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Hermansky-Pudlak Syndrome (HPS) cohort.

Asset / SponsorPhaseRating
PRAVASTATIN
National Human Genome Research Institute (NHGRI)
Phase 1/2CCC
Zileuton
National Human Genome Research Institute (NHGRI)
Phase 1/2CCC
Erythromycin
National Human Genome Research Institute (NHGRI)
Phase 1/2CCC
N-Acetyl-L-Cysteine
National Human Genome Research Institute (NHGRI)
Phase 1/2CCC
Losartan
National Human Genome Research Institute (NHGRI)
Phase 1/2CCC
PANITUMUMAB
National Human Genome Research Institute (NHGRI)
Phase 1/2CCC

Same molecule, other indications

Doxycycline is also rated in:

lymphangioleiomyomatosisDormant
BB
Indicative ·
64 / 100
View asset →
tuberous sclerosisDormant
BB
Indicative ·
64 / 100
View asset →
Chronic Pelvic Pain SyndromeDormant
B
Indicative ·
62 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →